Androgens, androgen suppression, and prostate cancer: Recent preclinical and clinical findings and implications

Jeanny B. Aragon-Ching, Nima Sharifi, James L. Gulley

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Prostate cancer is the leading cause of malignancy among American men and the third leading cause of cancer deaths. Approximately 42% of men will progress following local definitive therapy, with either rising PSA or metastatic disease. Androgen-deprivation therapy (ADT) is the primary treatment for metastatic prostate cancer. Although it is increasingly used in different disease stages and patient populations, there is still controversy regarding its use in patients whose sole determinant of disease progression is rising PSA. Various treatment modalities have been studied in combination with ADT to determine their overall efficacy and benefit in terms of progression-free and overall survival, leading to the use of ADT in selected patient populations. However, ADT is not without side effects. Different dosing strategies, such as intermittent ADT and rapid hormonal cycling, are being employed to determine how to administer ADT for maximum benefit and minimal toxicity. For the many patients who will eventually develop incurable, often debilitating metastatic castrate-resistant disease, strategies for directing novel therapies at the androgen-receptor signaling pathway and apoptotic genes hold future promise. This chapter discusses the clinical applications, side effects, and overall effects of ADT, clinical studies that support or controvert its use in selected patient populations and stages of prostate cancer, and the biology of castrate-resistant prostate cancer and novel approaches to its treatment.

Original languageEnglish (US)
Title of host publicationAndrogens: Production, Functions and Disorders
PublisherNova Science Publishers, Inc.
Pages165-220
Number of pages56
ISBN (Print)9781620811450
StatePublished - Aug 2012

Fingerprint

Androgens
Prostatic Neoplasms
Therapeutics
Androgen Receptors
Toxicity
Population
Genes
Disease-Free Survival
Disease Progression
Cause of Death
Neoplasms

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Aragon-Ching, J. B., Sharifi, N., & Gulley, J. L. (2012). Androgens, androgen suppression, and prostate cancer: Recent preclinical and clinical findings and implications. In Androgens: Production, Functions and Disorders (pp. 165-220). Nova Science Publishers, Inc..

Androgens, androgen suppression, and prostate cancer : Recent preclinical and clinical findings and implications. / Aragon-Ching, Jeanny B.; Sharifi, Nima; Gulley, James L.

Androgens: Production, Functions and Disorders. Nova Science Publishers, Inc., 2012. p. 165-220.

Research output: Chapter in Book/Report/Conference proceedingChapter

Aragon-Ching, JB, Sharifi, N & Gulley, JL 2012, Androgens, androgen suppression, and prostate cancer: Recent preclinical and clinical findings and implications. in Androgens: Production, Functions and Disorders. Nova Science Publishers, Inc., pp. 165-220.
Aragon-Ching JB, Sharifi N, Gulley JL. Androgens, androgen suppression, and prostate cancer: Recent preclinical and clinical findings and implications. In Androgens: Production, Functions and Disorders. Nova Science Publishers, Inc. 2012. p. 165-220
Aragon-Ching, Jeanny B. ; Sharifi, Nima ; Gulley, James L. / Androgens, androgen suppression, and prostate cancer : Recent preclinical and clinical findings and implications. Androgens: Production, Functions and Disorders. Nova Science Publishers, Inc., 2012. pp. 165-220
@inbook{971f39d59c6b479caf2dae711b3dad47,
title = "Androgens, androgen suppression, and prostate cancer: Recent preclinical and clinical findings and implications",
abstract = "Prostate cancer is the leading cause of malignancy among American men and the third leading cause of cancer deaths. Approximately 42{\%} of men will progress following local definitive therapy, with either rising PSA or metastatic disease. Androgen-deprivation therapy (ADT) is the primary treatment for metastatic prostate cancer. Although it is increasingly used in different disease stages and patient populations, there is still controversy regarding its use in patients whose sole determinant of disease progression is rising PSA. Various treatment modalities have been studied in combination with ADT to determine their overall efficacy and benefit in terms of progression-free and overall survival, leading to the use of ADT in selected patient populations. However, ADT is not without side effects. Different dosing strategies, such as intermittent ADT and rapid hormonal cycling, are being employed to determine how to administer ADT for maximum benefit and minimal toxicity. For the many patients who will eventually develop incurable, often debilitating metastatic castrate-resistant disease, strategies for directing novel therapies at the androgen-receptor signaling pathway and apoptotic genes hold future promise. This chapter discusses the clinical applications, side effects, and overall effects of ADT, clinical studies that support or controvert its use in selected patient populations and stages of prostate cancer, and the biology of castrate-resistant prostate cancer and novel approaches to its treatment.",
author = "Aragon-Ching, {Jeanny B.} and Nima Sharifi and Gulley, {James L.}",
year = "2012",
month = "8",
language = "English (US)",
isbn = "9781620811450",
pages = "165--220",
booktitle = "Androgens: Production, Functions and Disorders",
publisher = "Nova Science Publishers, Inc.",

}

TY - CHAP

T1 - Androgens, androgen suppression, and prostate cancer

T2 - Recent preclinical and clinical findings and implications

AU - Aragon-Ching, Jeanny B.

AU - Sharifi, Nima

AU - Gulley, James L.

PY - 2012/8

Y1 - 2012/8

N2 - Prostate cancer is the leading cause of malignancy among American men and the third leading cause of cancer deaths. Approximately 42% of men will progress following local definitive therapy, with either rising PSA or metastatic disease. Androgen-deprivation therapy (ADT) is the primary treatment for metastatic prostate cancer. Although it is increasingly used in different disease stages and patient populations, there is still controversy regarding its use in patients whose sole determinant of disease progression is rising PSA. Various treatment modalities have been studied in combination with ADT to determine their overall efficacy and benefit in terms of progression-free and overall survival, leading to the use of ADT in selected patient populations. However, ADT is not without side effects. Different dosing strategies, such as intermittent ADT and rapid hormonal cycling, are being employed to determine how to administer ADT for maximum benefit and minimal toxicity. For the many patients who will eventually develop incurable, often debilitating metastatic castrate-resistant disease, strategies for directing novel therapies at the androgen-receptor signaling pathway and apoptotic genes hold future promise. This chapter discusses the clinical applications, side effects, and overall effects of ADT, clinical studies that support or controvert its use in selected patient populations and stages of prostate cancer, and the biology of castrate-resistant prostate cancer and novel approaches to its treatment.

AB - Prostate cancer is the leading cause of malignancy among American men and the third leading cause of cancer deaths. Approximately 42% of men will progress following local definitive therapy, with either rising PSA or metastatic disease. Androgen-deprivation therapy (ADT) is the primary treatment for metastatic prostate cancer. Although it is increasingly used in different disease stages and patient populations, there is still controversy regarding its use in patients whose sole determinant of disease progression is rising PSA. Various treatment modalities have been studied in combination with ADT to determine their overall efficacy and benefit in terms of progression-free and overall survival, leading to the use of ADT in selected patient populations. However, ADT is not without side effects. Different dosing strategies, such as intermittent ADT and rapid hormonal cycling, are being employed to determine how to administer ADT for maximum benefit and minimal toxicity. For the many patients who will eventually develop incurable, often debilitating metastatic castrate-resistant disease, strategies for directing novel therapies at the androgen-receptor signaling pathway and apoptotic genes hold future promise. This chapter discusses the clinical applications, side effects, and overall effects of ADT, clinical studies that support or controvert its use in selected patient populations and stages of prostate cancer, and the biology of castrate-resistant prostate cancer and novel approaches to its treatment.

UR - http://www.scopus.com/inward/record.url?scp=84892034163&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892034163&partnerID=8YFLogxK

M3 - Chapter

AN - SCOPUS:84892034163

SN - 9781620811450

SP - 165

EP - 220

BT - Androgens: Production, Functions and Disorders

PB - Nova Science Publishers, Inc.

ER -